Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
- 9 September 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (10), 1184-1190
- https://doi.org/10.1161/01.cir.0000087447.12918.85
Abstract
Background— Complement, activated during myocardial ischemia and reperfusion, causes myocardial damage through multiple processes. The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial was performed to determine the effect of pexelizumab, a C5 complement inhibitor, on infarct size in patients with ST-segment–elevation myocardial infarction (MI) undergoing primary percutaneous coronary intervention. Methods and Results— In COMMA, 960 patients with MI (20% isolated inferior MI) were randomized to placebo, pexelizumab 2.0-mg/kg bolus, or pexelizumab 2.0-mg/kg bolus and 0.05-mg/kg per h infusion for 20 hours. Infarct size by creatine kinase–MB area under the curve, the primary outcome, did not differ significantly between groups (placebo median, 4393; bolus pexelizumab, 4526; bolus plus infusion pexelizumab, 4713 [ng/mL] · h; P=0.89 for bolus versus placebo; P=0.76 for bolus plus infusion versus placebo), nor did the composite of 90-day death, new or worsening heart failure, shock, or stroke (placebo, 11.1%; bolus, 10.7%; bolus plus infusion, 8.5%). The ninety-day mortality rate was significantly lower with pexelizumab bolus plus infusion (1.8% versus 5.9% with placebo; nominal P=0.014); the bolus-only group had an intermediate mortality rate (4.2%). Conclusions— In patients with ST-elevation MI undergoing percutaneous coronary intervention, pexelizumab had no measurable effect on infarct size. However, the significant reduction in mortality suggests that pexelizumab may benefit patients through alternative novel mechanisms and provides impetus for additional investigation.Keywords
This publication has 24 references indexed in Scilit:
- Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial InfarctionCirculation, 2003
- Cardiogenic Shock Complicating Acute Myocardial InfarctionCirculation, 2003
- C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/ReperfusionJournal of Pharmacology and Experimental Therapeutics, 2002
- Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarctionEuropean Heart Journal, 2002
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesionsKidney International, 1999
- Apoptosis in Human Acute Myocardial InfarctionCirculation, 1997
- Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.JCI Insight, 1995
- C5b-8 and C5b-9 modulate the collagen release of human glomerular epithelial cellsKidney International, 1990
- Detection of the terminal complement complex in patient plasma following acute myocardial infarctionAtherosclerosis, 1988